Worth Watching: Is Selling Intellia Therapeutics Inc Here a Winning Strategy?

Worth Watching: Is Selling Intellia Therapeutics Inc Here a Winning Strategy?

The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) reached all time low today, Oct, 18 and still has $10.85 target or 10.00% below today’s $12.06 share price. This indicates more downside for the $417.56 million company. This technical setup was reported by Barchart.com. If the $10.85 PT is reached, the company will be worth $41.76M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 105,247 shares traded hands. Intellia Therapeutics Inc (NASDAQ:NTLA) has risen 6.00% since September 18, 2016 and is uptrending. It has outperformed by 0.52% the S&P500.

Analysts await Intellia Therapeutics Inc (NASDAQ:NTLA) to report earnings on November, 3. After $-0.36 actual earnings per share reported by Intellia Therapeutics Inc for the previous quarter, Wall Street now forecasts -41.67% EPS growth.

Intellia Therapeutics Inc (NASDAQ:NTLA) Ratings Coverage

Out of 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Intellia Therapeutics has been the topic of 5 analyst reports since May 31, 2016 according to StockzIntelligence Inc. The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) earned “Outperform” rating by Leerink Swann on Friday, August 5. Wedbush initiated Intellia Therapeutics Inc (NASDAQ:NTLA) on Tuesday, May 31 with “Outperform” rating. Jefferies initiated it with “Hold” rating and $33 target price in Tuesday, May 31 report. The rating was upgraded by Jefferies on Friday, August 5 to “Buy”. Credit Suisse initiated Intellia Therapeutics Inc (NASDAQ:NTLA) rating on Tuesday, May 31. Credit Suisse has “Outperform” rating and $39 price target.

According to Zacks Investment Research, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.”

More important recent Intellia Therapeutics Inc (NASDAQ:NTLA) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on April 16, 2016, also Globenewswire.com published article titled: “Intellia Therapeutics to Present at September Investor Healthcare Conferences”, Globenewswire.com published: “Intellia Therapeutics to Present at 2016 Wedbush PacGrow Healthcare Conference” on August 10, 2016. More interesting news about Intellia Therapeutics Inc (NASDAQ:NTLA) was released by: Marketwatch.com and their article: “Intellia Therapeutics trading above issue price in market debut” with publication date: May 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment